March 2002

Contents

Special reports

• Meeting calls for NHS funding and training to provide repair treatment for people with facial lipoatrophy

Antiretrovirals

• Hepatic injury with nevirapine related to drug level and hepatitis C infection

• Study finds that PI-containing regimens have a beneficial effect on oral candidiasis independent of any immune reconstitution

• Tenofovir DF approved for marketing in European Union

• It may be important to screen and treat riboflavin deficiency in patients on nucleoside analogues

• Factors associated with immunologic stability despite protease inhibitor based HAART “failure”

• NIAID funds 9-year, 6,000-participant study to look at how best to use antiretrovirals

Treatment access

• South African treatment activists defy patent laws to import generic antiretrovirals from Brazil

Side effects

• Managing the metabolic side effects of antiretroviral therapy

• Intensive diet and exercise regimen may help fight lipodystrophy

• Avascular necrosis (AVN) may be increasingly common in HIV-positive patients

• Rheumatological complications associated with the use of indinavir and other protease inhibitors

Basic science and immunology

• Reseeding of viral reservoirs may explain poor response to HAART interruption

Other news

• Smoking damages quality of life for people with HIV, says study

• Nutritional supplements can help people gain weight, raise CD4 counts

• HIV-like virus detected in wild chimpanzee

On the web

• The Body launches major new feature section on HIV+ women

• The role of IL-10 in long-term non-progressors

• Therapeutic immunisation: a vaccine by any other name

• Immune-based therapies for HIV: a history

• IL-2: promiscuous cytokine or steady date

• Wondering aloud: theories of one (quasi) LTNP

• The immune system: behind the scenes

• Immune restoration: repairing the damage

PDFs

• Volume 3 Number 2 March 2002 PDF